CROs in France

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

French CRO providing Phase I-III clinical development services with particular expertise in metabolic disease, endocrinology, and cardiovascular trials across Europe.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

French CDMO specialising in topical, semi-solid, and liquid pharmaceutical manufacturing for clinical trial supply and commercial production.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

French mid-size CRO specialising in Phase I-III clinical trials, biostatistics, and regulatory affairs with offices in Paris and North Africa.